PF 3882845

Drug Profile

PF 3882845

Alternative Names: PF-03882845; PF-3882845

Latest Information Update: 12 Nov 2012

Price : $50

At a glance

  • Originator Pfizer
  • Class Indazoles
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic nephropathies; Type 2 diabetes mellitus

Most Recent Events

  • 09 Aug 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in Belgium (PO)
  • 09 Aug 2012 Discontinued - Phase-I for Diabetic nephropathies in Singapore (PO)
  • 09 Aug 2012 Discontinued - Phase-I for Diabetic nephropathies in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top